New insights into the rational use of HCV+ organs worldwide.

Jose M Morales, Deirdre Sawinski

Journal: Clinical transplantation 2020;33(12):e13739

PMID: 31648391

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Hepatitis C (HCV) is a worldwide health problem. Effective therapies for HCV infection, coupled with an increase in deceased donors due to the opioid epidemic, have led to the broader availability and the use of HCV-infected donor organs, including HCV nucleic acid test-positive (NAT+) donors in HCV-negative recipients. In this review, we discuss the prevalence of HCV infection, trends in the use of HCV-infected donors, and outcomes for those who receive HCV-seropositive or HCV NAT+ donor organs. We discuss management considerations such as hepatitis B reactivation, selection of the optimal direct-acting antiviral regimen, and potential complications. We also present a framework for the rational use of HCV-infected donor organs in the future.

Address: Research Institute, Hospital 12 de Octubre, Complutense University, Madrid, Spain.; Renal, Electrolyte and Hypertension Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.

DOI: 10.1111/ctr.13739

Link outs

Free resources

Medical:

https://medlineplus.gov/organdonation.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Antiviral Agents, Donor Selection, Hepacivirus, Hepatitis C, Humans, Organ Transplantation, Tissue Donors, Tissue and Organ Procurement